Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $89 and keeps an Outperform rating on the shares following the Q2 report. The firm says the company will release the Phase 2b data for aleniglipron by the end of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Reports Q2 2025 Financial Results
- Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
- Structure Therapeutics files automatic mixed securities shelf
- Structure Therapeutics initiated with a Buy at Clear Street
- Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs